LY3015014 + Placebo + Statin + Ezetimibe
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia
Trial Timeline
Jun 1, 2013 → Jun 1, 2014
NCT ID
NCT01890967About LY3015014 + Placebo + Statin + Ezetimibe
LY3015014 + Placebo + Statin + Ezetimibe is a phase 2 stage product being developed by Eli Lilly for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01890967. Target conditions include Hypercholesterolemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01890967 | Phase 2 | Completed |
Competing Products
20 competing products in Hypercholesterolemia